Autolus Therapeutics (AUTL) 46th Annual William Blair Growth Stock Conference summary

Commercial progress and financial performance

• Achieved market leadership in relapsed refractory acute leukemia with product launches in the US, UK, and Europe, generating GBP 74 million in revenue last year and $26 million in Q1 2026.

• Guidance for 2024 is $120–$135 million in revenue, with presence in 76 centers and plans to exceed 80 by year-end.

• Transitioned to a positive gross profit margin in Q1, aiming for 65–70% mature gross margin as operational efficiency improves.

• Manufacturing facility north of London supports individualized CAR T-cell therapy with >90% success rate and plans to double output this year, reducing cost of goods.

• Expansion focuses on deeper adoption within existing centers rather than adding many new sites, targeting broader physician engagement.

Clinical development and pipeline updates

• Lead product approved for relapsed/refractory acute leukemia; pivotal pediatric study ongoing with data expected end of next year.

• Pivotal lupus nephritis study underway with mid-2028 data readout; progressive multiple sclerosis (BOBCAT study) to provide initial data by year-end and full data next year.

• Early clinical programs in autoimmune diseases and plasma cell disorders, with next data from AUTO8 in amyloidosis expected at year-end.

• Real-world data confirm >90% complete remission rate and favorable safety profile, including low high-grade toxicity and no treatment-related mortality.

• Pediatric ALL pivotal study shows >90% remission and good safety; expansion aims to cover all age groups and phenotypes.

Market dynamics and adoption trends

• CAR T penetration in adult ALL was ~10% before launch; product profile enables treatment of older and sicker patients, expanding eligible population.

• Physicians report treating patients previously ineligible for CAR T due to improved safety, with potential to reach 60% penetration in relapsed/refractory setting.

• UK launch deemed cost-efficient, entering routine commissioning without need for additional data; EU market access pursued country by country.

• Gene and cell therapies currently excluded from most favored nation pricing proposals, supporting differentiated market positioning.